Nutrition21 transitions to applied dna's certaint® platform to secure ip-protected portfolio of dietary supplement ingredients

Stony brook, n.y.--(business wire)---- $apdn--applied dna sciences, inc. (nasdaq: apdn) (“applied dna” or the "company"), a leader in polymerase chain reaction (pcr)-based dna manufacturing, today announced the expansion of commercial activities under its multi-year master services agreement (msa) with nutrition21 whereby nutrition21 has transitioned to applied dna's certaint® platform to secure its ip-protected portfolio of dietary supplement ingredients. concurrently, the company received two follow-on
APDN Ratings Summary
APDN Quant Ranking